Sökning: WFRF:(Lorizio W.) > CYP2D6 Genotype and...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 10875naa a2200949 4500 | |
001 | oai:DiVA.org:oru-33895 | |
003 | SwePub | |
008 | 140224s2014 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-338952 URI |
024 | 7 | a https://doi.org/10.1038/clpt.2013.1862 DOI |
040 | a (SwePub)oru | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Province, M. A.u Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis MO, USA4 aut |
245 | 1 0 | a CYP2D6 Genotype and Adjuvant Tamoxifen :b Meta-Analysis of Heterogeneous Study Populations |
264 | c 2013-09-23 | |
264 | 1 | a New York, USA :b Nature Publishing Group,c 2014 |
338 | a print2 rdacarrier | |
500 | a Funding Agencies:National Institutes of Health (National Institute of General Medical Sciences)National Institutes of Health (National Cancer Institute)National Institutes of Health (National Institute of Child Health and Human Development)Breast Cancer Research (Scotland) Tayside Tissue Bank California Breast Cancer Research Program Cancer Research UK Deutsches Krebsforschungszentrum, Heidelberg, Germany Robert Bosch Foundation, Stuttgart, Germany Marie Curie Initial Training Network "FightingDrugFailure" GrantStichting Emmanuel van der Schueren (scientific partner of the Vlaamse Liga tegen Kanker) National Project for Personalized Genomic Medicine, Ministry for Health & Welfare, Republic of Korea Deutsche Forschungsgemeinschaft, Germany | |
520 | a The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis on data from 4,973 tamoxifen-treated patients (12 globally distributed sites). Using strict eligibility requirements (postmenopausal women with estrogen receptor-positive breast cancer, receiving 20 mg/day tamoxifen for 5 years, criterion 1), CYP2D6 poor metabolizer status was associated with poorer invasive disease-free survival (IDFS: hazard ratio = 1.25; 95% confidence interval = 1.06, 1.47; P = 0.009). However, CYP2D6 status was not statistically significant when tamoxifen duration, menopausal status, and annual follow-up were not specified (criterion 2, n = 2,443; P = 0.25) or when no exclusions were applied (criterion 3, n = 4,935; P = 0.38). Although CYP2D6 is a strong predictor of IDFS using strict inclusion criteria, because the results are not robust to inclusion criteria (these were not defined a priori), prospective studies are necessary to fully establish the value of CYP2D6 genotyping in tamoxifen therapy. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmakologi och toxikologi0 (SwePub)301022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmacology and Toxicology0 (SwePub)301022 hsv//eng |
653 | a Medicine | |
653 | a Medicin | |
700 | 1 | a Goetz, M. P.u Department of Oncology and Pharmacology, Mayo Clinic, Rochester MN, USA4 aut |
700 | 1 | a Brauch, H.u Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Tübingen University, Tübingen, Germany4 aut |
700 | 1 | a Flockhare, D. A.u Division of Clinical Pharmacology, School of Medicine, Indiana University, Bloomington IN, USA4 aut |
700 | 1 | a Hebert, J. M.u Department of Genetics, School of Medicine, Stanford University, Stanford CA, USA4 aut |
700 | 1 | a Whaley, R.u Department of Genetics, School of Medicine, Stanford University, Stanford CA, USA4 aut |
700 | 1 | a Suman, V. J.u Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester MO, USA4 aut |
700 | 1 | a Schroth, W.u Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Tübingen University, Tübingen, Germany4 aut |
700 | 1 | a Winter, S.u Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology and University, Tuebingen, Germany4 aut |
700 | 1 | a Zembutsu, H.u Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan4 aut |
700 | 1 | a Mushiroda, T.u Laboratory for Pharmacogenetics, RIKEN Center for Genomic Medicine, Yokohama, Japan4 aut |
700 | 1 | a Newman, W. G.u Centre for Genetic Medicine, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK; Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK4 aut |
700 | 1 | a Lee, M-TM.u Laboratory for International Alliance, RIKEN Center for Genomic Medicine, Yokohama, Japan4 aut |
700 | 1 | a Ambrosone, C. B.u Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo NY, USA4 aut |
700 | 1 | a Beckmann, M. W.u Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany4 aut |
700 | 1 | a Choi, J-Yu Department of Biomedical Science, Graduate School, Seoul National University, Seoul, Korea4 aut |
700 | 1 | a Dieudonne, A-Su Department of Oncology, Catholic University Leuven, Leuven, Belgium4 aut |
700 | 1 | a Fasching, P. A.u Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles CA, USA4 aut |
700 | 1 | a Ferraldeschi, R.u Centre for Genetic Medicine, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK; Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK4 aut |
700 | 1 | a Gong, L.u Department of Genetics, School of Medicine, Stanford University, Stanford CA, USA4 aut |
700 | 1 | a Haschke-Becher, E.u University Institute of Medical and Chemical Laboratory Diagnostics, Paracelsus Private Medical University, Salzburg, Austria4 aut |
700 | 1 | a Howel, A.u The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK4 aut |
700 | 1 | a Jordan, L. B.u Department of Pathology, Ninewells Hospital and Medical School, Dundee, UK4 aut |
700 | 1 | a Hamann, U.u Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum, Heidelberg, Germany4 aut |
700 | 1 | a Kiyotani, K.u Laboratory for Pharmacogenetics, RIKEN Center for Genomic Medicine, Yokohama, Japan4 aut |
700 | 1 | a Krippl, P.u Medical University Graz, Graz, Austria4 aut |
700 | 1 | a Lambrechts, D.u Vesalius Research Center, VIB and Laboratory of Translational Genetics, Department of Oncology, Catholic University Leuven, Leuven, Belgium4 aut |
700 | 1 | a Latif, A.u Centre for Genetic Medicine, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK; Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK4 aut |
700 | 1 | a Langsenlehner, U.u Medical University Graz, Graz, Austria4 aut |
700 | 1 | a Lorizio, W.u Division of General Internal Medicine, Department of Medicine and Clinical Pharmacology and Experimental Therapeutics, and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco CA, USA4 aut |
700 | 1 | a Neven, P.u Department of Gynecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium4 aut |
700 | 1 | a Nguyen, A. T.u Division of Clinical Pharmacology, School of Medicine, Indiana University, Bloomington IN, USA4 aut |
700 | 1 | a Park, B-W.u Department of Surgery, Yonsei University Health System, Seoul, Korea4 aut |
700 | 1 | a Purdie, C. A.u Department of Pathology, Ninewells Hospital and Medical School, Dundee, UK4 aut |
700 | 1 | a Quinlan, P.u Dundee Cancer Centre, Dundee, UK4 aut |
700 | 1 | a Renner, W.u Medical University Graz, Graz, Austria4 aut |
700 | 1 | a Schmidt, M.u Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University Tübingen, Tübingen, Germany; Department of Gynecology and Obstetrics, University of Mainz, Mainz, Germany4 aut |
700 | 1 | a Schwab, M.u Department of Clinical Pharmacology and Toxicology, University Hospital Tuebingen, Tuebingen, Germany4 aut |
700 | 1 | a Shin, J-Gu Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine, Busan, Korea; Department of Clinical Pharmacology, Inje University Busan Paik Hospital, Busan, Korea4 aut |
700 | 1 | a Stingl, J. C.u Division of Research, Federal Institute for Drugs and Medical Devices, University of Bonn Medical Faculty, Bonn, Germany4 aut |
700 | 1 | a Wegman, Pia,d 1964-u Örebro universitet,Hälsoakademin4 aut0 (Swepub:oru)ppk |
700 | 1 | a Wingren, Sten,d 1950-u Örebro universitet,Institutionen för läkarutbildning4 aut0 (Swepub:oru)snwn |
700 | 1 | a Wu, A. H. B.u Department of Laboratory Medicine, University of California, San Francisco CA, USA4 aut |
700 | 1 | a Ziv, E.u Division of General Internal Medicine, Department of Medicine and Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco CA, USA4 aut |
700 | 1 | a Zirpoli, G.u Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo NY, USA4 aut |
700 | 1 | a Thompson, A. M.u Dundee Cancer Centre, Dundee, UK4 aut |
700 | 1 | a Jordan, V. C.u Department of Oncology, Georgetown University, Washington DC, USA4 aut |
700 | 1 | a Nakamura, Y.u Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan4 aut |
700 | 1 | a Altman, R. B.u Department of Genetics, School of Medicine, Stanford University, Stanford CA, USA; Department of Bioengineering, Stanford University, Stanford CA, USA4 aut |
700 | 1 | a Ames, M. M.u Department of Pharmacology, Mayo Clinic, Rochester MN, USA4 aut |
700 | 1 | a Klein, T. E.u Department of Genetics, School of Medicine, Stanford University, Stanford CA, USA4 aut |
710 | 2 | a Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis MO, USAb Department of Oncology and Pharmacology, Mayo Clinic, Rochester MN, USA4 org |
773 | 0 | t Clinical Pharmacology and Therapeuticsd New York, USA : Nature Publishing Groupg 95:2, s. 216-227q 95:2<216-227x 0009-9236x 1532-6535 |
856 | 4 | u https://doi.org/10.1038/clpt.2013.186y Fulltext |
856 | 4 | u https://europepmc.org/articles/pmc3904554?pdf=render |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-33895 |
856 | 4 8 | u https://doi.org/10.1038/clpt.2013.186 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy